Production (Stage)
Cardiff Oncology, Inc.
CRDF
$3.86
$0.051.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -3.61% | 40.16% | 49.78% | 61.41% | 54.43% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -3.61% | 40.16% | 49.78% | 61.41% | 54.43% |
| Cost of Revenue | 23.60% | 12.16% | 10.68% | 12.75% | 9.89% |
| Gross Profit | -24.14% | -11.74% | -10.10% | -12.06% | -9.27% |
| SG&A Expenses | 2.11% | -4.30% | -8.96% | -11.27% | 6.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.34% | 7.48% | 4.83% | 5.20% | 8.79% |
| Operating Income | -17.63% | -7.13% | -4.36% | -4.65% | -8.35% |
| Income Before Tax | -21.44% | -9.63% | -5.34% | -3.07% | -3.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -21.44% | -9.63% | -5.34% | -3.07% | -3.33% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -21.44% | -9.63% | -5.34% | -3.07% | -3.33% |
| EBIT | -17.63% | -7.13% | -4.36% | -4.65% | -8.35% |
| EBITDA | -17.82% | -7.18% | -4.33% | -4.55% | -8.13% |
| EPS Basic | -3.84% | -3.20% | -3.82% | -2.20% | -1.68% |
| Normalized Basic EPS | -3.86% | -3.19% | -3.80% | -2.18% | -1.68% |
| EPS Diluted | -3.84% | -3.20% | -3.82% | -2.20% | -1.68% |
| Normalized Diluted EPS | -3.86% | -3.19% | -3.80% | -2.18% | -1.68% |
| Average Basic Shares Outstanding | 18.87% | 6.65% | 1.39% | 0.93% | 1.63% |
| Average Diluted Shares Outstanding | 18.87% | 6.65% | 1.39% | 0.93% | 1.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |